Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoxin'an capsule observational effectiveness study in stroke
ChiCTR2500110680Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Oct 2025
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naoxin'an capsule in ischemic stroke, cerebrovascular disease and coronary arteriosclerosis, sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoints: Improvement of neurological deficits (changes in NIHSS score), Changes in consciousness (changes in GCS score) and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
naoxin'an capsule
03
Conditions
ischemic strokecerebrovascular diseasecoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500110680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110680.